The phase 3 study of Coronavac, a vaccine produced by the Chinese company Sinovac and brought to Brazil in partnership with the government of São Paulo, has gathered the minimum required infection data to have its effectiveness analyzed.
The expectation of the Butantan Institute, sponsor of the study, is that the Independent International Committee, which accompanies the trials, will analyze these data and disclose the vaccine's effectiveness in the first week of December.
If everything goes well and works, the data will be sent immediately to Anvisa (National Health Surveillance Agency). If approved within the express deadline expected by the health emergency, in January there will be 46 million doses purchased from China and ready to be applied.
If all are applied, half the population of the state of São Paulo may be vaccinated as early as 2021.
Translated by Kiratiana Freelon